Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 8/20 | 0.39 |
| ▸ | CTSD | P07339 | 4/20 | 0.38 |
| ▸ | BACE1 | P56817 | 4/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976386 | 0.91 | CTSD (0.39) | CCR1CTSDBACE1BACE2UTS2R | |
| SCHEMBL976518 | 0.91 | CTSD (0.39) | CCR1CTSDBACE1BACE2UTS2R | |
| SCHEMBL976499 | 0.87 | UTS2R (0.39) | CTSDBACE1BACE2UTS2RCA1 | |
| SCHEMBL977320 | 0.87 | CNR2 (0.40) | CCR1CTSDBACE1BACE2UTS2R | |
| SCHEMBL975116 | 0.87 | UTS2R (0.39) | CCR1CTSDBACE1BACE2UTS2R | |
| SCHEMBL976522 | 0.86 | CTSD (0.41) | CCR1CTSDBACE1BACE2UTS2R | |
| SCHEMBL3401770 | 0.85 | CTSD (0.39) | CTSDBACE1BACE2UTS2RTDP1 | |
| SCHEMBL3661019 | 0.85 | MEN1 (0.38) | CTSDBACE1BACE2UTS2RLMNA | |
| SCHEMBL978276 | 0.85 | CTSD (0.39) | CCR1CTSDBACE1BACE2UTS2R | |
| SCHEMBL976506 | 0.85 | CCR1 (0.36) | CCR1CA1CA2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | claimed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| EP-2234966-B1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI SA (FR) | 2013-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | CCR1 1721/4885CTSD 1694/4885BACE1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.